Drug Search Results
More Filters [+]

Burapitant

Alternative Names: burapitant, SSR240600C
Latest Update: 2016-05-26
Latest Update Note: Clinical Trial Update

Product Description

Burapitant (SSR-240,600) is a drug developed by Sanofi-Aventis which was one of the first compounds developed that acts as a potent and selective antagonist for the NK1 receptor. Burapitant inhibited the binding of radioactive substance P to tachykinin NK1 receptors in human lymphoblastic IM9 cells, human astrocytoma U373MG cells, and human brain cortex. (Sourced from: https://drugs.ncats.io/drug/E35SK332MS)

Mechanisms of Action: NK1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Burapitant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Overactive Bladder|Enuresis|Urinary Incontinence, Urge

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2007-004126-24

P2

Completed

Overactive Bladder|Urinary Incontinence, Urge

2009-02-07

BILADY

P2

Completed

Overactive Bladder|Urinary Incontinence, Urge

2009-02-01

MILADY

P2

Completed

Urinary Incontinence, Urge|Enuresis|Overactive Bladder

2006-05-01

Recent News Events

Date

Type

Title